#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5180	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2526	590.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1826	1826	T	815	T,G	712,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5180	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2526	590.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1560	1560	C	785	C,A,G	626,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8418	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4003	608.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1848	1848	A	682	A	587	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8418	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4003	608.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2482	2482	C	636	C,T	537,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8418	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4003	608.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2556	2556	A	644	A,C	556,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8418	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4003	608.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3108	3108	C	713	C	597	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	692	folP	855	855	100.0	folP.l6.c4.ctg.1	1884	107.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1230	1232	AGC	131;132;132	A;G;C,T	116;117;113,1	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1776	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3878	133.4	1	SNP	p	S91F	1	.	.	271	273	TTC	815	817	TTC	138;138;140	T;T;C	116;115;119	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1776	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3878	133.4	1	SNP	p	D95G	1	.	.	283	285	GGC	827	829	GGC	142;142;143	G;G;C	118;119;116	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1776	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3878	133.4	1	SNP	p	G95N	0	.	.	283	285	GGC	827	829	GGC	142;142;143	G;G;C	118;119;116	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	810	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1746	135.7	1	SNP	p	G45D	0	.	.	133	135	GGC	686	688	GGC	220;218;218	G,T;G;C	174,1;172;173	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	504	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1375	106.7	0	.	n	.	0	A197.	DEL	197	197	A	738	738	A	213	A	181	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1612	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3361	139.7	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1610	1612	GTC	199;198;197	G;T,G;C	164;163,1;164	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1612	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3361	139.7	1	SNP	p	D86N	0	.	.	256	258	GAC	716	718	GAC	144;142;143	G,T;A;C	108,1;108;113	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1612	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3361	139.7	1	SNP	p	R87I	0	.	.	259	261	CGT	719	721	CGT	145;144;144	C;G;T,G	112;115;114,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1612	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3361	139.7	1	SNP	p	S87R	1	.	.	259	261	CGT	719	721	CGT	145;144;144	C;G;T,G	112;115;114,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1612	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3361	139.7	1	SNP	p	R87W	0	.	.	259	261	CGT	719	721	CGT	145;144;144	C;G;T,G	112;115;114,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1612	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3361	139.7	1	SNP	p	S88P	0	.	.	262	264	TCC	722	724	TCC	144;142;140	T;C;C	113;115;110	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1412	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3039	135.3	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1546	1548	TGC	166;167;169	T,G,C;G,T;C	127,4,1;126,1;136	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1412	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3039	135.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1756	1758	GGC	177;177;176	G;G;C	149;145;147	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1552	1554	GCA	190;187;187	G;C;A	161;153;156	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1555	1557	ATC	187;186;186	A,C;T,A;C,T	154,2;154,1;158,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1567	1569	GTG	185;184;186	G,T;T,C;G	161,1;149,1;156	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1567	1569	GTG	185;184;186	G,T;T,C;G	161,1;149,1;156	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2071	2073	ACC	146;146;146	A;C;C,G	113;128;121,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2125	2127	GCG	144;144;143	G;C;G	121;113;116	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2125	2127	GCG	144;144;143	G;C;G	121;113;116	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2248	2250	GGC	171;171;170	G,C;G;C,G	142,1;144;142,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2257	2259	GGC	175;175;175	G,C;G,T;C,A	148,1;149,1;144,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1480	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2928	146.0	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2275	2277	TCG	183;181;182	T,G;C;G	146,1;145;149	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1766	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3538	144.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1866	1868	CCG	136;137;136	C;C;G,C	112;107;108,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	936	porA	1146	1146	99.56	porA.l15.c17.ctg.1	2060	131.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	672	672	C	151	C,A	119,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1254	1256	AAT	15;15;15	A;A;T	12;12;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1257	1259	AAT	15;15;15	A;A;T	11;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1281	1283	GCA	14;14;14	G;C;A	12;9;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1304	1306	GTA	14;14;14	G;T;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1310	1312	AAC	14;14;14	A;A;C	11;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1314	1318	TGGCG	14;14;14;14;14	T;G;G;C;G	12;11;11;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1320	1322	GCT	13;13;13	G;C;T	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1380	1382	TTA	11;11;11	T;T;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1425	1427	CAT	14;14;14	C;A;T	11;9;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1428	1430	AGT	14;14;14	A;G;T	11;11;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	128	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1526	24.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1437	1439	TAC	14;14;14	T;A;C	11;11;11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	356	358	GAA	257;258;255	G,A;A,C;A	210,2;217,1;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	644	646	GAT	240;240;240	G;A,G;T	194;191,1;191	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	767	769	TCA	218;219;219	T,A,G;C;A	185,1,1;189;195	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	896	898	GTC	192;194;193	G;T;C	155;170;170	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1226	1228	GCA	193;193;194	G;C,T;A	173;166,1;171	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	1	SNP	p	G120K	1	.	.	358	360	AAG	602	604	AAG	246;246;247	A;A;G,T	201;207;202,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	1	SNP	p	D121N	0	.	.	361	363	GAC	605	607	GAC	246;244;245	G;A;C,A	203;195;190,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1108	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1525	197.4	1	SNP	p	A121D	1	.	.	361	363	GAC	605	607	GAC	246;244;245	G;A;C,A	203;195;190,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	120	porB3	990	113	92.04	porB3.l6.c30.ctg.2	907	15.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	846	848	ACG	29;29;29	A;C;G	25;25;24	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	120	porB3	990	113	92.04	porB3.l6.c30.ctg.2	907	15.6	0	.	p	.	0	T29A	NONSYN	85	87	ACC	879	881	GCC	24;24;24	G;C;C	23;23;21	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	120	porB3	990	113	92.04	porB3.l6.c30.ctg.2	907	15.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	888	890	CAA	18;18;18	C;A;A	17;17;16	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	120	porB3	990	113	92.04	porB3.l6.c30.ctg.2	907	15.6	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	894	896	TAC	16;16;15	T;A;C	15;15;14	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3422	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5316	186.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2229	2231	AAT	189;190;191	A;A,C;T,G	156;156,1;153,2	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	542	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1282	124.5	1	SNP	p	V57M	1	.	.	169	171	ATG	662	664	ATG	198;194;194	A;T;G	167;167;168	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
